Literature DB >> 29351983

Partial tandem duplication of KMT2A (MLL) may predict a subset of myelodysplastic syndrome with unique characteristics and poor outcome.

Sarah M Choi1, Rajan Dewar2, Patrick W Burke3, Lina Shao2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29351983      PMCID： PMC5830365          DOI： 10.3324/haematol.2017.185249

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Mutation analysis for RUNX1, MLL-PTD, FLT3-ITD, NPM1 and NRAS in 269 patients with MDS or secondary AML.

Authors:  F Dicker; C Haferlach; J Sundermann; N Wendland; T Weiss; W Kern; T Haferlach; S Schnittger
Journal:  Leukemia       Date:  2010-06-03       Impact factor: 11.528

2.  MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition.

Authors:  Michael W M Kühn; Michael J Hadler; Scott R Daigle; Richard P Koche; Andrei V Krivtsov; Edward J Olhava; Michael A Caligiuri; Gang Huang; James E Bradner; Roy M Pollock; Scott A Armstrong
Journal:  Haematologica       Date:  2015-01-16       Impact factor: 9.941

3.  Clinical and biological implications of partial tandem duplication of the MLL gene in acute myeloid leukemia without chromosomal abnormalities at 11q23.

Authors:  H-S Shiah; Y-Y Kuo; J-L Tang; S-Y Huang; M Yao; W Tsay; Y-C Chen; C-H Wang; M-C Shen; D-T Lin; K-H Lin; H-F Tien
Journal:  Leukemia       Date:  2002-02       Impact factor: 11.528

4.  Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML.

Authors:  S Schnittger; U Kinkelin; C Schoch; A Heinecke; D Haase; T Haferlach; T Büchner; B Wörmann; W Hiddemann; F Griesinger
Journal:  Leukemia       Date:  2000-05       Impact factor: 11.528

5.  The partial tandem duplication of ALL1 (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia.

Authors:  M P Strout; G Marcucci; C D Bloomfield; M A Caligiuri
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

6.  Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients.

Authors:  R Kihara; Y Nagata; H Kiyoi; T Kato; E Yamamoto; K Suzuki; F Chen; N Asou; S Ohtake; S Miyawaki; Y Miyazaki; T Sakura; Y Ozawa; N Usui; H Kanamori; T Kiguchi; K Imai; N Uike; F Kimura; K Kitamura; C Nakaseko; M Onizuka; A Takeshita; F Ishida; H Suzushima; Y Kato; H Miwa; Y Shiraishi; K Chiba; H Tanaka; S Miyano; S Ogawa; T Naoe
Journal:  Leukemia       Date:  2014-02-03       Impact factor: 11.528

7.  Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics.

Authors:  M A Caligiuri; M P Strout; D Lawrence; D C Arthur; M R Baer; F Yu; S Knuutila; K Mrózek; A R Oberkircher; G Marcucci; A de la Chapelle; E Elonen; A W Block; P N Rao; G P Herzig; B L Powell; T Ruutu; C A Schiffer; C D Bloomfield
Journal:  Cancer Res       Date:  1998-01-01       Impact factor: 12.701

8.  Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm.

Authors:  Konstanze Döhner; Karen Tobis; Regina Ulrich; Stefan Fröhling; Axel Benner; Richard F Schlenk; Hartmut Döhner
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

Review 9.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

10.  ALL-1 partial duplication in acute leukemia.

Authors:  S A Schichman; M A Caligiuri; Y Gu; M P Strout; E Canaani; C D Bloomfield; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205
View more
  4 in total

1.  Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Jun Kong; Meng-Ge Gao; Ya-Zhen Qin; Yu Wang; Chen-Hua Yan; Yu-Qian Sun; Ying-Jun Chang; Lan-Ping Xu; Xiao-Hui Zhang; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Su Zhao
Journal:  BMC Cancer       Date:  2022-01-03       Impact factor: 4.430

Review 2.  Transcriptional addiction in mixed lineage leukemia: new avenues for target therapies.

Authors:  Ruijing Xiao; Honghong Wang; Kaiwei Liang
Journal:  Blood Sci       Date:  2019-09-17

3.  Allelic complexity of KMT2A partial tandem duplications in acute myeloid leukemia and myelodysplastic syndromes.

Authors:  Harrison K Tsai; Christopher J Gibson; H Moses Murdock; Phani Davineni; Marian H Harris; Eunice S Wang; Lukasz P Gondek; Annette S Kim; Valentina Nardi; R Coleman Lindsley
Journal:  Blood Adv       Date:  2022-07-26

4.  High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance.

Authors:  Hui Yang; Guillermo Garcia-Manero; Koji Sasaki; Guillermo Montalban-Bravo; Zhenya Tang; Yue Wei; Tapan Kadia; Kelly Chien; Diana Rush; Ha Nguyen; Awdesh Kalia; Manjunath Nimmakayalu; Carlos Bueso-Ramos; Hagop Kantarjian; L Jeffrey Medeiros; Rajyalakshmi Luthra; Rashmi Kanagal-Shamanna
Journal:  Leukemia       Date:  2022-08-01       Impact factor: 12.883
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.